Biggest News Aggregation in the World
📰 Renal Dysfunction News

Renal Dysfunction News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Renal Dysfunction. Real-time updates on events, politics, business and more.

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

AstraZeneca: LYNPARZA (olaparib) and IMFINZI (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial

Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA (olaparib), IMFINZI(durvalumab), chemotherapy and bevacizumab demonstrated
France General United States United Kingdom Brendan Mcevoy Jessica Mcduell Susan Galbraith

LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial

Positive results from a planned interim analysis of the DUO-O Phase III trial showed that treatment with a combination of LYNPARZA® , IMFINZI® , chemotherapy and bevacizumab demonstrated a... | June 3, 2023
France General United Kingdom United States Susan Galbraith National Cancer Institute European Society Of Medical Oncology Congress

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science